コンテンツへスキップ
Merck
  • Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience.

Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience.

Pediatric neurology (2012-04-24)
Martina Vendrame, Laura M F F Guilhoto, Tobias Loddenkemper, Matt Gregas, Blaise F Bourgeois, Sanjeev V Kothare
要旨

Retrospective review was performed of children aged <3 years with epileptic spasms at our center from 2004-2010. Short-term (<6 months) and long-term (≥6 months) outcomes were assessed. We included 173 children (104 boys; median age of onset, 6.8 months) with epileptic spasms of known (62%) and unknown (38%) etiology. Treatments included adrenocorticotropic hormone (n = 103), vigabatrin (n = 82), phenobarbital (n = 34), and other agents (n = 121). Short-term treatment with adrenocorticotropic hormone and vigabatrin provided better epileptic spasm control in groups with known and unknown etiology than other agents. At follow-up (6-27 months), 54% of children manifested seizures, and 83% manifested developmental delay. Known etiology was a predictor of poor developmental outcome (P = 0.006), whereas bilateral/diffuse brain lesions predicted both poor development and seizures (P = 0.001 and 0.005, respectively). Initial presentations of epileptic spasms with hypotonia or developmental delay most strongly predicted both seizures and neurodevelopmental outcomes (P < 0.001). In a child presenting with epileptic spasms with developmental delay or hypotonia, no specific treatment may offer superior benefit.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(±)-ビガバトリン
Supelco
Vigabatrin solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®